PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Tirzepatide>>benefits
Approved medicine

Tirzepatide Benefits: Trial Endpoints Summarized

Tirzepatide’s registrational programs produced some of the largest pharmacological weight and glycemic effects ever published. This page lists the actual endpoints.

Weight outcomes

SURMOUNT-1 (n=2,539, 72 weeks): −20.9% mean weight reduction at 15 mg versus −3.1% placebo; over half of participants at the highest dose lost ≥20%. SURMOUNT-2 and -3 extended results to type 2 diabetes and intensive-lifestyle populations respectively.

Glycemic outcomes

The SURPASS program in type 2 diabetes reported HbA1c reductions up to ~2.3 percentage points at the highest dose, outperforming semaglutide 1 mg, dulaglutide, and insulin degludec in head-to-head comparisons.

Obstructive sleep apnea

SURMOUNT-OSA reported meaningful reduction in apnea–hypopnea index in adults with obesity and moderate-to-severe OSA, both with and without PAP therapy.

The caveat

As with all incretin data, these are trial-condition effects with structured follow-up. Tolerability-driven discontinuation and post-discontinuation regain are documented characteristics of the class.

Educational content only — not medical advice. Dosing and treatment decisions belong with the approved label and a prescriber.

References

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. [source]
  2. ClinicalTrials.gov — registered tirzepatide studies. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement